Glycemic Control and Iron Status in Diabetic Pregnancies - a Study of New Markers
NCT ID: NCT03330951
Last Updated: 2020-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2016-05-31
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Women with diabetes are at increased risk for adverse pregnancy outcomes. With improved glycemic control, the risk decreases. Glycated albumin is suggested to be a better marker for monitoring glycemic control in pregnancies because it reflects blood glucose for a shorter period than HbA1c (3 versus 8-12 weeks). Other studies have shown that HbA1c increases in pregnancy because of iron deficiency. The investigators want to investigate HbA1c, glycated albumin and iron status in diabetic pregnancies. The investigators will compare HbA1c and glycated albumin throughout pregnancy with the patient's own blood glucose measurements or data from CGM (continuous blood glucose monitoring). Blood samples for HbA1c and glycated albumin will be taken 6 times during pregnancy (week 12, 20, 24, 28, 32, 36).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glycated Albumin in Pregnancy
NCT03372824
Fetal Cardiac Function Parameters and HbA1c As Screening for Gestational Diabetes Mellitus
NCT05019508
The Use of Early Pregnancy HbA1c in Predicting Excessive Fetal Growth in Women at Risk of Glucose Intolerance
NCT04858386
Gestational Diabetes Mellitus: "Placental-maternal Crosstalk and Future Health"
NCT05872009
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
NCT06048510
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* singleton pregnancy
* follow-up at Stavanger University Hospital in pregnancy
Exclusion Criteria
* twin pregnancies
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helse Stavanger HF
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johanne Toft, MD
Role: PRINCIPAL_INVESTIGATOR
Helse Stavanger HF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stavanger University Hospital
Stavanger, Rogaland, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUS-ID580
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.